natgillin/translations-raw huggingface dataset:
It is also appropriate to perform baseline investigations of erythrocyte sedimentation rate or other inflammatory markers, lung function/chest X-ray and renal function prior to initiation of therapy.
Primerno je tudi, da se pred začetkom zdravljenja opravijo osnovne preiskave hitrosti sedinmentacije eritrocitov ali drugih kazalcev vnetja, rentgenski pregled pljučnega delovanja/prsnega koša in ledvičnega delovanja.
“Very common side effect (affecting more than one person in ten): heart valve and related disorders e.g. inflammation (pericarditis) or leaking of fluid in the pericardium (pericardial effusion).
“Zelo pogosti neželeni učinki (ki jih izkusi več kot ena oseba od desetih): obolenja srčne zaklopke in druga sorodna obolenja, npr. vnetje (perikarditis, t.j.
If fibrotic valvular disease is detected, the patient should not be treated with cabergoline (see section 4.3).
Če odkrijemo fibrotično valvularno bolezen, zdravljenje s kabergolinom ni dovoljeno (glejte poglavje 4.3).
“- have or had fibrotic reactions (scar tissue) affecting your heart.”
“- imate ali ste imeli fibrotične reakcije (brazgotinasto tkivo), ki so prizadele vaše srce.”
ANNEX III AMENDMENTS TO THE SUMMARIES OF PRODUCT CHARACTERISTICS AND PACKAGE LEAFLETS
ANEKS III SPREMEMBE POVZETKA GLAVNIH ZNAČILNOSTI ZDRAVILA IN NAVODILA ZA UPORABO
“Evidence of cardiac valvulopathy as determined by pre-treatment echocardiography.”
“Znaki srčne valvulopatije, ugotovljene z ehokardiografijo pred začetkom zdravljenja..”
Additional appropriate investigations such as erythrocyte sedimentation rate, and serum creatinine measurements should be performed if necessary to support a diagnosis of a fibrotic disorder.”
Po potrebi je zaradi dokazovanja diagnoze fibrotičnega obolenja treba opraviti ustrezne dodatne preiskave, kot sta hitrost sedimentacije eritrocitov in serumski kreatinin."
“If you have or had fibrotic reactions (scar tissue) affecting your heart, lungs or abdomen.
“Če imate ali ste ste imeli fibrotične reakcije (brazgotinasto tkivo), ki so prizadele vaše srce, pljuča ali trebuh.
Section 2 “Before you take [product name]”.
Poglavje 2 “Kaj morate vedeti, preden boste vzeli zdravilo [ime zdravila]”:
“-will be treated with [product name] for a long period and have or had fibrotic reactions (scar tissue) affecting your heart.”
„- se boste z zdravilom [ime zdravila] zdravili dolgo časa in imate oziroma ste imeli fibrozne reakcije (brazgotinsko tkivo), ki so vplivale na vaše srce.“
Fibrotic and serosal inflammatory disorders such as pleuritis, pleural effusion, pleural fibrosis, pulmonary fibrosis, pericarditis, pericardial effusion, cardiac valvulopathy involving one or more valves (aortic, mitral and tricuspid) or retroperitoneal fibrosis have occurred after prolonged usage of ergot derivatives with agonist activity at the serotonin 5HT2B receptor, such as pergolide.
Po dolgotrajnejši uporabi ergot derivatov z delovanjem na serotoninske receptorje 5HT2B, kakršen je pergolid, so se pojavila fibrotična in serozna vnetna obolenja, kot so plevritis, plevralni izliv, plevralna fibroza, pljučna fibroza, perikarditis, perikardialni izliv, srčna valvulopatija, ki prizadene eno ali več zaklopk (aortno, mitralno in trikuspidalno) ali retroperitonealna fibroza.
Fibrotic and serosal inflammatory disorders such as pleuritis, pleural effusion, pleural fibrosis, pulmonary fibrosis, pericarditis, pericardial effusion, cardiac valvulopathy involving one or more valves (aortic, mitral and tricuspid) or retroperitoneal fibrosis have occurred after prolonged usage of ergot derivatives with agonist activity at the serotonin 5HT2B receptor, such as cabergoline.
Po dolgotrajnejši uporabi ergot derivatov z delovanjem na serotoninske receptorje 5HT2B, kakršen je kabergolin, so se pojavila fibrotična in serozna vnetna obolenja, kot so plevritis, plevralni izliv, plevralna fibroza, pljučna fibroza, perikarditis, perikardialni izliv, srčna valvulopatija, ki prizadene eno ali več zaklopk (aortno, mitralno in trikuspidalno) ali retroperitonealna fibroza.
Clinical diagnostic monitoring for development of valvular disease or fibrosis, as appropriate, is essential.
Nujno potrebno je klinično diagnostično spremljanje, skladno s potrebami, zaradi možnosti nastanka valvularne bolezni ali fibroze.
4.2 Posology and method of administration The following should be reflected as appropriate: Restriction of the maximum dose to 3 mg/day
Najvišji dnevni odmerek je omejen na 3 mg/dan
AMENDMENTS TO BE INCLUDED IN THE RELEVANT SECTIONS OF THE SUMMARY OF PRODUCT CHARACTERISTICS FOR PERGOLIDE CONTAINING MEDICINAL PRODUCTS
SPREMEMBE, KI JIH JE POTREBNO VKLJUČITI V USTREZNA POGLAVJA POVZETKA GLAVNIH ZNAČILNOSTI ZDRAVILA ZA VSA ZDRAVILA, KI VSEBUJEJO PERGOLID
AMENDMENTS TO BE INCLUDED IN THE RELEVANT SECTIONS OF THE SUMMARY OF PRODUCT CHARACTERISTICS FOR CABERGOLINE CONTAINING MEDICINAL PRODUCTS
SPREMEMBE, KI JIH JE POTREBNO VKLJUČITI V USTREZNA POGLAVJA POVZETKA GLAVNIH ZNAČILNOSTI ZDRAVILA ZA VSA ZDRAVILA, KI VSEBUJEJO KABERGOLIN
Clinical diagnostic monitoring for development of fibrotic disorders, as appropriate, is essential.
Nujno potrebno je klinično diagnostično spremljanje, skladno s potrebami, zaradi možnosti nastanka fibrotičnih obolenj.
Therefore, during treatment, attention should be paid to the signs and symptoms of: Pleuro-pulmonary disease such as dyspnoea, shortness of breath, persistent cough or chest pain.
plevro-pljučne bolezni, kot je dispneja, kratka sapa, vztrajen kašelj ali bolečine v prsnem košu.
AMENDMENTS TO BE INCLUDED IN THE RELEVANT SECTIONS OF THE PACKAGE LEAFLET FOR PERGOLIDE CONTAINING MEDICINAL PRODUCTS
POPRAVKI, KI JIH JE POTREBNO VKLJUČITI V USTREZNA POGLAVJA NAVODILA ZA UPORABO PRI VSEH ZDRAVILIH, KI VSEBUJEJO PERGOLID
AMENDMENTS TO BE INCLUDED IN THE RELEVANT SECTIONS OF THE PACKAGE LEAFLET FOR CABERGOLINE CONTAINING MEDICINAL PRODUCTS
POPRAVKI, KI JIH JE POTREBNO VKLJUČITI V USTREZNA POGLAVJA NAVODILA ZA UPORABO PRI VSEH ZDRAVILIH, KI VSEBUJEJO KABERGOLIN
Ref. EMEA/CHMP/494914/2008
EMEA/CHMP/494934/2008
The procedure started on 22 March 2007.
Postopek se je začel 22. marca 2007.
London, 3 September 2008 Doc.
London, 3. september 2008 Ref. dok.
A Decision was issued by the European Commission on 3 September 2008.
Odločbo je Evropska komisija izdala 3. septembra 2008.
The Marketing Authorisation Holder provided supplementary information on 23 July 2007.
Imetnik dovoljenja za promet z zdravilom je posredoval dodatne informacije 23. julija 2007.
Cozaar Comp and associated names, 50/12.5 mg; 100/12.5 mg; 100/25 mg, film coated tablets is a fixed dose combination of losartan and hydrochlorothiazide.
Zdravilo Cozaar Comp in povezana imena, 50/12,5 mg; 100/12,5 mg; 100/25 mg, filmsko obložene tablete, je kombinacija fiksnih odmerkov losartana in hidroklorotiazida.
Losartan is an orally active angiotensin II (Ang- II) receptor antagonist acting on the AT1 receptor subtype, thus blocking the effect of Ang-II in the renin angiotensin system (RAS) cascade.
Losartan je peroralno aktivni antagonist receptorjev angiotenzina II (Ang- II), ki deluje na receptorje podtipa AT1 in tako blokira učinek Ang-II v kaskadi renin-angiotenzinskega sistema (RAS).
Hydrochlorothiazide (HCTZ) is a thiazide diuretic which has also been used as an antihypertensive agent.
Hidroklorotiazid (HCTZ) je tiazidni diuretik, ki se uporablja tudi kot antihipertenziv.
The basis for referral was that there were divergences in the Summaries of Product Characteristics (SPC) of Cozaar Comp. and associated names approved across EU Member States, with respect to the following indications: Treatment of hypertension in patients whose blood pressure is not adequately controlled on losartan or hydrochlorothiazide; As first step treatment in patients with moderate to severe hypertension and in patients with high or very high cardiovascular risk; Reduction of cardiovascular morbidity and mortality in hypertensive patients with left ventricular hypertrophy.
Podlaga za napotitev so bile ugotovljene razlike v odobrenih povzetkih glavnih značilnosti zdravila za zdravilo Cozaar Comp in povezana imena v različnih državah članicah EU v zvezi z indikacijami: zdravljenje hipertenzije pri bolnikih, pri katerih krvnega tlaka ni mogoče ustrezno nadzorovati samo z losartanom ali hidroklortiazidom; prva stopnja zdravljenja bolnikov z zmerno do resno hipertenzijo in bolnikov z visokim ali zelo visokim srčnožilnim tveganjem; zmanjšanje kardiovaskularne obolevnosti in smrtnosti pri hipertenzivnih bolnikih s hipertrofijo levega prekata.
On 23 February 2007, Denmark presented to the EMEA a referral under Article 30 of Directive 2001/83/EC, as amended, in order to harmonise the nationally authorised summaries of product characteristics, package leaflet and labelling of the medicinal product Cozaar Comp. and associated names.
Dne 23. februarja 2007 je Danska agenciji EMEA predložila napotitev v skladu s členom 30 Direktive 2001/83/ES, kakor je bila spremenjena, da bi tako uskladili nacionalno odobrene povzetke glavnih značilnosti zdravila, navodila za uporabo in označevanje za zdravilo Cozaar Comp in povezana imena.
The losartan/hydrochlorothiazide combination is indicated for the treatment of hypertension in patients whose blood pressure is not adequately controlled on losartan or hydrochlorothiazide.
Kombinacija losartan/hidroklorotiazid je namenjena za zdravljenje hipertenzije pri bolnikih, pri katerih samo z losartanom ali hidroklortiazidom ni mogoče ustrezno uravnavati krvnega tlaka.
The list of product names concerned is given in Annex I. The scientific conclusions are provided in Annex II together with the amended SPC, labelling and package leaflet in Annex III.
Seznam zadevnih imen izdelkov je naveden v Dodatku I. Znanstveni zaključki so na voljo v Dodatku II, spremenjeni povzetek glavnih značilnosti zdravila, označevanje in navodilo za uporabo pa v Dodatku III.
During its 21 - 24 April 2008 meeting, the CHMP, in the light of the overall submitted data and the scientific discussion within the Committee, was of the opinion that the proposal for the harmonisation of the SPC, Labelling and Package leaflet was acceptable and that they should be amended.
Med zasedanjem od 21. do 24. aprila 2008 je CHMP na podlagi vseh posredovanih podatkov in znanstvene razprave v okviru Odbora, sprejel mnenje, da je predlog za uskladitev povzetkov glavnih značilnosti zdravila, označevanja in navodila za uporabo sprejemljiv ter da jih je treba ustrezno spremeniti.
The CHMP gave a positive opinion on 24 April 2008 recommending the harmonisation of the SPC, labelling and package leaflet for Cozaar Comp. and associated names.
CHMP je 24. aprila 2008 izdal pozitivno mnenje, s katerim priporoča uskladitev povzetkov glavnih značilnosti zdravila, označevanja in navodila za uporabo za Cozaar Comp. in povezana imena.
COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) OPINION FOLLOWING AN ARTICLE 30 REFERRAL FOR Cozaar Comp and associated names International Non-Proprietary Name (INN): losartan + hydrochlorothiazide
Mednarodno nelastniško ime (INN): losartan + hidroklorotiazid
The European Commission issued a decision on 7 July 2010.
Evropska komisija je odločbo izdala dne 7. julija 2010.
Harald Enzmann (Germany)
Harald Enzmann (Nemčija)
It is used to treat the following types of cancer:
Uporablja se za zdravljenje naslednjih vrst raka:
Jean-François Baurain (Belgium)
Jean-François Baurain (Belgija)
Bendamustine has been used in anticancer medicines in Germany since the early 1970s.
Bendamustin se v Nemčiji v zdravilih proti raku uporablja od začetka sedemdesetih let prejšnjega stoletja.
What are the conclusions of the CHMP?
Do kakšnih zaključkov je prišel CHMP?
Why was Levact reviewed?
Zakaj je bilo zdravilo Levact pregledano?
As a result, the cancer cells cannot divide and the growth of tumours slows down.
Celice raka se tako ne morejo deliti in rast tumorjev se upočasni.
The European Medicines Agency has completed an arbitration procedure following a disagreement among Member States of the European Union (EU) regarding the authorisation of the medicine Levact and associated names.
Evropska agencija za zdravila je končala postopek arbitraže, do katerega je prišlo po nesoglasju med državami članicami Evropske unije (EU) glede odobritve zdravila Levact in povezanih imen.
Co-Rapporteur:
Soporočevalec:
It binds to the DNA of cells while they are reproducing, which stops cell division.
Veže se na DNK celic med njihovim razmnoževanjem, kar preprečuje delitev celic.
However, the Member States were not able to reach an agreement and the German medicines regulatory agency referred the matter to the CHMP for arbitration on 2 October 2009.
Vendar države članice niso mogle doseči soglasja in nemška regulativna agencija za zdravila je dne 2. oktobra 2009 zadevo napotila na CHMP v arbitražo.
14 January 2010 and 17 February 2010
14. januarja 2010 in 17. februarja 2010
The grounds for the referral were that one Member State, the United Kingdom, could not approve the indication non-Hodgkin's lymphoma, and two Member States, Belgium and France, could not approve the indication multiple myeloma because not enough data on the effectiveness of this medicine were available to support these indications.
Podlaga za napotitev je bila, da ena država članica, Združeno kraljestvo, ni mogla odobriti indikacije ne-Hodgkinov limfom, dve državi članici, Belgija in Francija, pa nista mogli odobriti indikacije multipli mielom, saj ni bilo dovolj podatkov glede učinkovitosti tega zdravila pri teh indikacijah.
The Committee therefore recommended that Levact be granted marketing authorisation in Germany and all concerned Member States for all the indications that were applied for.
Odbor je tako priporočil odobritev dovoljenja za promet z zdravilom Levact v Nemčiji in v vseh zadevnih državah članicah za vse indikacije, za katere je bila vložena vloga.
This is a procedure where one Member State (the ‘reference Member State', in this instance Germany) assesses a medicine with a view to granting a marketing authorisation that will be valid in this country as well as in other Member States (the ‘concerned Member States', in this instance Belgium, Denmark, Finland, France, Ireland, Italy, Luxembourg, Norway, Poland, Spain and the United Kingdom).
To je postopek, v katerem ena država članica („referenčna država članica“, v tem primeru Nemčija) oceni zdravilo z namenom odobritve dovoljenja za promet z njim, ki bo veljavno v tej državi in v drugih državah članicah („zadevne države članice“, v tem primeru Avstrija, Belgija, Danska, Finska, Francija, Irska, Italija, Luksemburg, Norveška, Poljska, Španija in Združeno kraljestvo).
Astellas Pharma GmbH submitted Levact to the German medicines regulatory agency for a decentralised procedure.
Družba Astellas Pharma GmbH je nemški regulativni agenciji predložila zdravilo Levact v decentralizirani postopek.
22 October 2009
22. oktober 2009
Based on the evaluation of these data and the scientific discussion within the Committee, the CHMP concluded that the benefits of Levact outweigh its risks for the two indications for which objections were raised.
Na podlagi ocene teh podatkov in znanstvene razprave v Odboru je CHMP menil, da koristi zdravila Levact odtehtajo njegova tveganja pri obeh indikacijah, pri katerih so se pojavili zadržki.
The Agency's Committee for Medicinal Products for Human Use (CHMP) has concluded that the benefits of Levact outweigh its risks, and that the marketing authorisation can be granted in Germany and in the following Member States: Austria, Belgium, Denmark, Finland, France, Ireland, Italy, Luxembourg, Norway, Poland, Spain and the United Kingdom.
Odbor za zdravila za uporabo v humani medicini (CHMP) pri agenciji je zaključil, da koristi zdravila Levact odtehtajo njegova tveganja in da se lahko dovoljenje za promet z zdravilom odobri v Nemčiji ter v navedenih državah članicah: Avstrija, Belgija, Danska, Finska, Francija, Irska, Italija, Luksemburg, Norveška, Poljska, Španija in Združeno kraljestvo.
The CHMP assessed the two clinical studies presented by the company to support the multiple myeloma and non-Hodgkin's lymphoma indications.
CHMP je ocenil dve klinični študiji, ki ju je družba predložila v podporo indikacijama multipli mielom in ne-Hodgkinov limfom.
Levact is an anticancer medicine.
Levact je zdravilo proti raku.
Questions and answers on Levact and associated names (bendamustine hydrochloride, 2.5 mg/ml, powder for concentrate for solution for infusion) EMA/CHMP/735863/2009
Vprašanja in odgovori v zvezi z zdravilom Levact in povezanimi imeni (bendamustin hidroklorid, 2,5 mg/ml, prašek za koncentrat za raztopino za infundiranje) EMA/CHMP/735863/2009
Company responses provided on:
Odgovori družbe, poslani dne:
18 March 2010
18. marec 2010
7 July 2010
7. julij 2010
Levact is also known as Ribomustin.
Zdravilo Levact je znano tudi kot zdravilo Ribomustin
The active substance in Levact, bendamustine hydrochloride, belongs to a group of anticancer medicines called ‘alkylating agents'.
Zdravilna učinkovina v zdravilu Levact, bendamustin hidroklorid, spada v skupino zdravil proti raku, imenovanih „alkilirajoče učinkovine“.
• non-Hodgkin's lymphoma (a cancer of the lymph tissue, part of the immune system) in patients whose cancer got worse during or following treatment containing rituximab (another anticancer medicine);
• ne-Hodgkinovega limfoma (raka limfnega tkiva, dela imunskega sistema) pri bolnikih, pri katerih se je rak poslabšal med zdravljenjem z zdravilom, ki vsebuje rituksimab (drugo zdravilo proti raku), ali po njem;
• chronic lymphocytic leukaemia (a cancer of a type of white blood cell called lymphocytes) in patients for whom treatment with fludarabine (another anticancer medicine) is not appropriate;
• kronične limfocitne levkemije (rak belih krvnih celic, imenovanih limfociti) pri bolnikih, pri katerih zdravljenje s fludarabinom (drugim zdravilom proti raku) ni ustrezno;
Questions and answers on Levact and associated names (bendamustine hydrochloride, 2.5 mg/ml, powder for concentrate for solution for infusion)
(bendamustin hidroklorid, 2,5 mg/ml, prašek za koncentrat za raztopino za infundiranje)
Referral start date:
Datum začetka napotitvenega postopka:
What is Levact?
Kaj je zdravilo Levact?
• multiple myeloma (a cancer of the bone marrow) in combination with prednisone in patients older than 65 years who are not eligible for stem-cell transplantation and cannot be treated with thalidomide or bortezomib (other anticancer medicines).
65 let, ki niso primerni za presaditev matičnih celic in jih ni mogoče zdraviti s talidomidom ali bortezomibom (drugima vrstama zdravil proti raku).
Although side effects were common, they appeared to be within acceptable limits.
Čeprav so bili neželeni učinki pogosti, so ti znotraj dopustnih meja.
Further planned or ongoing studies are expected to provide more information on Trumenba's effectiveness.
Načrtovane ali potekajoče študije naj bi zagotovile več informacij o učinkovitosti zdravila Trumenba.
Other information about Trumenba
Druge informacije o zdravilu Trumenba
This is a summary of the European public assessment report (EPAR) for Trumenba.
To je povzetek evropskega javnega poročila o oceni zdravila (EPAR) za zdravilo Trumenba.
What measures are being taken to ensure the safe and effective use of Trumenba?
Kateri ukrepi se izvajajo za zagotovitev varne in učinkovite uporabe zdravila Trumenba?
The full EPAR for Trumenba can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Celotno evropsko javno poročilo o oceni zdravila (EPAR) za zdravilo Trumenba je na voljo na spletni strani agencije: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Initial treatment may either involve 2 injections at least 6 months apart, or 2 injections at least 1 month apart followed by a third injection at least 4 months later.
Začetno zdravljenje lahko vključuje bodisi dve injekciji v razmiku vsaj šestih mesecev ali dve injekciji v razmiku vsaj enega meseca, ki jima sledi tretja injekcija vsaj štiri mesece pozneje.
In patients at greater risk of invasive meningococcal disease, an additional booster dose may be considered later on.
Pri bolnikih z dodatnim tveganjem za invazivno meningokokno bolezen se lahko pozneje razmisli še o dodatnem obnovitvenem odmerku.
It is available in a pre-filled syringe and is given by injection into a muscle, preferably in the shoulder.
Na voljo je v napolnjeni injekcijski brizgi in se daje z injiciranjem v mišico, najbolje v ramo.
The Agency's Committee for Medicinal Products for Human Use (CHMP) concluded that based on available data Trumenba's benefits are greater than its risks and recommended that it be approved for use in the EU.
Odbor za zdravila za uporabo v humani medicini (CHMP) pri agenciji je zaključil, da so koristi zdravila Trumenba večje od z njim povezanih tveganj, in priporočil, da se odobri za uporabo v EU.
The most common side effects with Trumenba (which may affect more than 1 in 10 people) are pain, redness or swelling at the site of the injection, headache, tiredness, chills, diarrhoea, nausea (feeling sick), and muscle or joint pain.
Najpogostejši neželeni učinki zdravila Trumenba (ki se lahko pojavijo pri več kot 1 osebi od 10) so bolečina, pordelost ali oteklina na mestu injiciranja, glavobol, utrujenost, mrzlica, driska, navzeja (slabost) in bolečine v mišicah ali sklepih.
Antibody responses were also seen against the 10 secondary strains and confirmed the responses seen with the 4 main strains.
Opazili so tudi odziv protiteles proti desetim sekundarnim sevom ter potrdili odzive, opažene proti štirim glavnim sevom.
What benefits of Trumenba have been shown in studies?
Kakšne koristi je zdravilo Trumenba izkazalo v študijah?
Invasive disease occurs when these bacteria spread through the body causing serious infections such as meningitis (infection of the membranes that surround the brain and spinal cord) and septicaemia (blood infection).
Invazivna bolezen se pojavi, ko se te bakterije razširijo po telesu in povzročijo resne okužbe, kot sta meningitis (okužba membran, ki obdajajo možgane in hrbtenjačo) in sepsa (okužba krvi).
What are the risks associated with Trumenba?
Kakšna tveganja so povezana z zdravilom Trumenba?
Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Trumenba have been included in the summary of product characteristics and the package leaflet.
Priporočila in varnostni ukrepi, ki jih morajo za varno in učinkovito uporabo zdravila Trumenba upoštevati zdravstveni delavci in bolniki, so vključeni v povzetek glavnih značilnosti zdravila in navodilo za njegovo uporabo.
As the protection provided seemed to decline over time, a booster dose should be considered in recipients who were thought to be at continued risk of invasive meningococcal disease.
Ker kaže, da zaščita sčasoma upada, je treba pri prejemnikih, pri katerih obstaja stalno tveganje za invazivno meningokokno bolezen, razmisliti o obnovitvenem odmerku.
For more information about treatment with Trumenba, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Za več informacij o zdravljenju z zdravilom Trumenba preberite navodilo za uporabo (ki je prav tako del EPAR) ali se posvetujte z zdravnikom ali farmacevtom.
Trumenba can only be obtained with a prescription and should be used according to official recommendations.
Predpisovanje in izdaja zdravila Trumenba je le na recept, uporabljati pa se mora v skladu z uradnimi priporočili.
What is Trumenba and what is it used for?
Kaj je zdravilo Trumenba in za kaj se uporablja?
In the second study sufficient amounts of antibodies were produced in 79 to 90% of cases, and protective levels of antibodies against all 4 strains were seen in 85% of participants.
V drugi študiji je nastalo dovolj protiteles pri 79 do 90 % primerov, zaščitne ravni protiteles proti vsem štirim sevom pa so opazili pri 85 % udeležencev.
Trumenba meningococcal group B vaccine (recombinant, adsorbed)
Trumenba cepivo proti meningokokom skupine B (rekombinantno, adsorbirano)
The studies also looked at response to 10 other, secondary strains of N. meningitidis group B.
V študijah so proučevali tudi odziv na deset drugih, sekundarnih sevov bakterije N. meningitidis skupine B.